Author:
Yildirim Yasemin,Sokmen Selman,Cevlik Ali Durubey,Bisgin Tayfun,Manoglu Berke,Obuz Funda
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Sugarbaker PH, Ryan DP (2012) Cytoreductive surgery plus hyperthermic perioperative chemotherapy to treat peritoneal metastases from colorectal cancer: standard of care or an experimental approach? Lancet Oncol 13(8):e362–e369
2. Said I, Ubink I, Ewalds RSG, Arkesteijn JGT, Verheul HMW, de Wilt JHW, Dekker HM, Bremers AJA, de Reuver PR (2022) In patients undergoing CRS/HIPEC for colorectal adenocarcinoma with peritoneal metastases, presence of ascites on computed tomography imaging is not a prognostic marker for survival. Ann Surg Oncol 29(8):5256–5262
3. Roxburgh CS, McMillan DC. Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer. 2014 Mar 18;110(6):1409–12. https://doi.org/10.1038/bjc.2014.90
4. Portilla AG, Sugarbaker PH, Chang D (1999) Second-look surgery after cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: analysis of prognostic features. World J Surg 23(1):23–29
5. Esquivel J, Farinetti A, Sugarbaker PH (1999) Chirurgia elettiva nella recidiva da cancro del colon con diffusione peritoneale: quando intervenire? [Elective surgery in recurrent colon cancer with peritoneal seeding: when to and when not to proceed]. G Chir 20(3):81-6. Italian